Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06321250
PHASE1
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Sponsor: Jemincare
View on ClinicalTrials.gov
Summary
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
Official title: An Open-label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-03-14
Completion Date
2027-04-30
Last Updated
2024-07-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
JMKX003948
Subjects will receive JMKX003948 tablets until disease progression
Locations (1)
Beijing Caancer Hospital
Beijing, China